CYTOMED THERAPEUTICS LTD (GDTC)
SGXZ17669631 - Common Stock
GDTC gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 561 industry peers in the Biotechnology industry. The financial health of GDTC is average, but there are quite some concerns on its profitability. GDTC does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
GDTC had negative earnings in the past year.
In the past year GDTC has reported a negative cash flow from operations.
GDTC had negative earnings in each of the past 5 years.
In the past 5 years GDTC always reported negative operating cash flow.
1.2 Ratios
GDTC has a better Return On Assets (-28.08%) than 70.45% of its industry peers.
GDTC has a Return On Equity of -30.14%. This is in the better half of the industry: GDTC outperforms 78.92% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -28.08% | ||
| ROE | -30.14% | ||
| ROIC | N/A |
ROA(3y)-42.33%
ROA(5y)-41.37%
ROE(3y)-215.47%
ROE(5y)-218.97%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for GDTC so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
Compared to 1 year ago, GDTC has about the same amount of shares outstanding.
The debt/assets ratio for GDTC has been reduced compared to a year ago.
2.2 Solvency
An Altman-Z score of 27.06 indicates that GDTC is not in any danger for bankruptcy at the moment.
GDTC has a Altman-Z score of 27.06. This is amongst the best in the industry. GDTC outperforms 95.14% of its industry peers.
A Debt/Equity ratio of 0.04 indicates that GDTC is not too dependend on debt financing.
The Debt to Equity ratio of GDTC (0.04) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.04 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 27.06 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
A Current Ratio of 21.53 indicates that GDTC has no problem at all paying its short term obligations.
GDTC's Current ratio of 21.53 is amongst the best of the industry. GDTC outperforms 95.50% of its industry peers.
GDTC has a Quick Ratio of 21.53. This indicates that GDTC is financially healthy and has no problem in meeting its short term obligations.
GDTC's Quick ratio of 21.53 is amongst the best of the industry. GDTC outperforms 95.50% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 21.53 | ||
| Quick Ratio | 21.53 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 59.90% over the past year.
EPS 1Y (TTM)59.9%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%57.52%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
Based on estimates for the next years, GDTC will show a quite strong growth in Earnings Per Share. The EPS will grow by 16.02% on average per year.
The Revenue is expected to grow by 9.59% on average over the next years. This is quite good.
EPS Next Y42.31%
EPS Next 2Y16.02%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year31.87%
Revenue Next 2Y9.59%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
GDTC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year GDTC is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
GDTC's earnings are expected to grow with 16.02% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y16.02%
EPS Next 3YN/A
5. Dividend
5.1 Amount
GDTC does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
CYTOMED THERAPEUTICS LTD
NASDAQ:GDTC (1/8/2025, 8:04:56 PM)
After market: 2.04 -0.25 (-10.92%)2.29
-0.67 (-22.64%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners0.04%
Inst Owner ChangeN/A
Ins Owners18%
Ins Owner Change0%
Market Cap26.43M
Analysts82.86
Price Target5.1 (122.71%)
Short Float %2.13%
Short Ratio2.83
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)11.76%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)9.81%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 3.56 | ||
| P/tB | 3.57 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.19
EYN/A
EPS(NY)-0.13
Fwd EYN/A
FCF(TTM)-0.22
FCFYN/A
OCF(TTM)-0.16
OCFYN/A
SpS0
BVpS0.64
TBVpS0.64
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -28.08% | ||
| ROE | -30.14% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-42.33%
ROA(5y)-41.37%
ROE(3y)-215.47%
ROE(5y)-218.97%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.04 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 275.79% | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 21.53 | ||
| Quick Ratio | 21.53 | ||
| Altman-Z | 27.06 |
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)103.86%
Cap/Depr(5y)210.93%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)59.9%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%57.52%
EPS Next Y42.31%
EPS Next 2Y16.02%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year31.87%
Revenue Next 2Y9.59%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y15.33%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-37.5%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-63.78%
OCF growth 3YN/A
OCF growth 5YN/A